The biopharmaceutical company has seen a mixed track record when it comes to current year estimate revisions over the past few weeks. However, the current year consensus for loss has widened over the last 30 days. This recent price action is discouraging, so make sure to keep a close watch on this firm in the near future, and especially on earnings estimates following the recent slump.
Tetraphase currently has a Zacks Rank #4 (Sell) while its Earnings ESP is 0.0%.
Some better-ranked stocks in the same sector include Shire (SHPG), Astellas Pharma, Inc. (ALPMY) and IntelliPharmaCeutics International Inc. (IPCI). All these stocks carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment